RecruitingNot ApplicableNCT05966649

Synbiotics in Patients at RIsk fOr Preterm Birth

Synbiotics in Patients at RIsk fOr Preterm Birth: a Multi-center Double-blind Randomized Placebo-controlled trIal


Sponsor

Ziekenhuis Oost-Limburg

Enrollment

402 participants

Start Date

Mar 16, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Prematurity remains the main cause of death and serious health problems in new-borns. Besides the need for hospitalization and medical interventions in the first weeks or months of the new-borns' life, prematurity can cause long-lasting health problems (e.g. multiple hospital admissions, developmental delay, learning difficulties, motor delay, hearing or eye problems, ...). Moreover, prematurity places an enormous economic burden on the society. Aside from the medical problems and the financial cost, the emotional stress and psychological impact on the parents, siblings and other family members should not be underestimated. Previous preterm delivery (before 37 weeks of pregnancy) increases the risk for recurrent preterm delivery in a subsequent pregnancy. Therefore, these women should be considered as 'high risk' for preterm birth. Infections ascending from the vagina may be an important cause of preterm delivery in certain cases. Some women have an abnormal vaginal microbiome and are therefore at risk for infections and preterm birth. On the other hand, the vaginal flora is more stable and resistant to infections in healthy pregnant women who deliver at term (after 37 weeks of gestation). Synbiotics are a mixture containing probiotics and prebiotics. Probiotics are living bacteria with potential beneficial effects that can be used safely in pregnancy, while prebiotics are consumed by the bacteria. It is known that probiotics, when used for a long period of time, can maintain a healthy and stable vaginal flora that may protect against infections. In this study, pregnant patients with a history of preterm birth will be included in the first trimester of pregnancy to start with synbiotics or placebo. The investigators will examine the effect of synbiotics on the vaginal flora and on the pregnancy duration. The hypothesis is that synbiotics, when started early in the pregnancy, can change the disturbed vaginal flora into a stable micro-environment.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and Synbiotics for people with microbial colonization, microbiome dysbiosis, and other related conditions. The study is currently recruiting participants at 9 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSynbiotics

Oral synbiotic (food supplement) containing 8 probiotic Lactobacillus strains, the prebiotics inulin, fructooligosaccharides (FOS) and D-mannose.

OTHERPlacebo

Matching placebo


Locations(9)

Universitaire Ziekenhuis Antwerpen

Edegem, Antwerpen, Belgium

Ziekenhuis Oost-Limburg

Genk, Limburg, Belgium

Universitaire Ziekenhuizen Leuven

Leuven, Limburg, Belgium

CHR Citadelle

Liège, Liège, Belgium

UZ Gent

Ghent, Oost-Vlaanderen, Belgium

AZ Sint-Jan

Bruges, West-Vlaanderen, Belgium

AZ Sint-Lucas

Bruges, West-Vlaanderen, Belgium

AZ Maria Middelares

Ghent, West-Vlaanderen, Belgium

AZ Groeninge

Kortrijk, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05966649


Related Trials